https://www.youtube.com/watch?v=nSXOz1ddSpI&feature=youtu.be
Ali Mortazavi, Chief Executive Officer at Silence Therapeutics plc (LON:SLN) spoke to Proactive Investors about their announcement of as Non-Executive Chair, Dr. Annalisa Jenkins.
https://www.youtube.com/watch?v=nSXOz1ddSpI&feature=youtu.be
Ali Mortazavi, Chief Executive Officer at Silence Therapeutics plc (LON:SLN) spoke to Proactive Investors about their announcement of as Non-Executive Chair, Dr. Annalisa Jenkins.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics plc, commented: “We reiterate that we will defend the Silence patent estate where we consider third parties to be infringing the company’s patent rights. As such, in Portugal
Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that that the company is scheduled to present
Silence Therapeutics plc (LON:SLN), a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that its annual report and financial statements for
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented: “2017 was a transformative and highly productive year for the Company. We believe Silence is well positioned to execute its strategy of transitioning into a drug development
Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that Ali Mortazavi, Chief Executive Officer, will
Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended
Silence Therapeutics plc, AIM:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that on 17 January 2018 the European Patent
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics LON:SLN, commented on the post year update: “At our recent Capital Markets Day, Silence demonstrated that it is now has a powerful, reproducible and modular GalNAc-siRNA platform that
Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that it has sold part of its
Silence Therapeutics plc, LON:SLNa leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will today host a Capital Markets Day for analysts, investors and
Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that the US Patent and Trade Mark Office
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics LON:SLN, commented on the appointment: “Annalisa’s appointment is a significant moment in the transition of Silence to a fully-integrated biopharma company. Her extensive and broad experience in all aspects
Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced that the US Patent and Trade Mark Office yesterday
Stephen Parker, Non-Executive Chairman of Silence Therapeutics LON:SLN, commented: “This period has seen a strong performance from all parts of the Company, with improved management and controls adding to the excellent progress of the research group.
Silence Therapeutics plc, LON:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results for the six
Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that the Company will host a Capital
Silence Therapeutics plc, LON:SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced this morning that the US Patent and Trade Mark
Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that it was advised on 2 August that